Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 4, 2003, Pages 687-700

  Becker, Axel ^a   Peters, Brigitte ^a   Schroeder, Helmut ^a   Mann, Tobias ^b   Huether, Gerald ^b   Grecksch, Gisela ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Anxiety; Dopamine binding sites; Dopamine transporter; Glutamate binding sites; Ketamine; Latent inhibition; Locomotor activity; Prepulse inhibition; Schizophrenia; Serotonin transporter; Social interaction

Indexed keywords

APOMORPHINE; DIZOCILPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; DRUG VEHICLE; GLUTAMATE RECEPTOR; KETAMINE; SEROTONIN TRANSPORTER; SODIUM CHLORIDE;

AGGRESSION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DENSITY; DOPAMINERGIC TRANSMISSION; FRONTAL CORTEX; HIPPOCAMPUS; ILLUMINATION; INJECTION; LATENT INHIBITION; LOCOMOTION; MALE; MAZE TEST; MOTOR ACTIVITY; NEUROTRANSMISSION; NONHUMAN; PARAMETER; PREPULSE INHIBITION; RAT; SCHIZOPHRENIA; SEROTONINERGIC TRANSMISSION; SOCIAL BEHAVIOR; SOCIAL INTERACTION;

EID: 0038012553     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(03)00080-0     Document Type: Article

References (115)

1. Abi-Saab W.M., D'Souza D.C., Moghaddam B., Krystal J.H. The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry. 31(Suppl. 2):1998;104-109.
2. Adler C.M., Malhotra A.K., Elman I., Goldberg T., Egan M., Pickar D., Breier A. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am. J. Psychiatry. 156:1999;1646-1649.
3. Allen R.M., Young S.J. Phencyclidine-induced psychosis. Am. J. Psychiatry. 135:1978;1081-1084.
4. Arditti J., Spadari M., de Haro L., Brun A., Bourdon J.H., Valli M. Ketamine - reves et realites. Acta Clin. Belg., Suppl. 2002;31-33.
5. Beardsley P.M., Balster R.L. Behavioral dependence upon phencyclidine and ketamine in the rat. J. Pharmacol. Exp. Ther. 242:1987;203-211.
6. Becker A., Grecksch G. Illumination has no effect on rats' behavior in the elevated plus-maze. Physiol. Behav. 59:1996;1175-1177.
7. Becker A., Grecksch G., Bernstein H.G., Hollt V., Bogerts B. Social behaviour in rats lesioned with ibotenic acid in the hippocampus: quantitative and qualitative analysis. Psychopharmacology (Berl.). 144:1999;333-338.
8. Benes F.M., Todtenkopf M.S., Logiotatos P., Williams M. Glutamate decarboxylase(65)-immunoreactive terminals in cingulate and prefrontal cortices of schizophrenic and bipolar brain. J. Chem. Neuroanat. 20:2000;259-269.
9. Bernstein H.-G., Becker A., Keilhoff G., Spilker C., Gorczyca A., Braunewell K.-H., Grecksch G. Brain region-specific changes in the expression of calcium sensor proteins after repeated applications of ketamine to rats. Neurosci. Lett. 339:2003;95-98.
10. Bodi T., Share I., Levy H., Moyer J.H. Clinical trials of phencyclidine (sernyl) in patients with psychoneurosis. Antibiot. Med. Clin. Ther. 6:1959;79-84.
11. Breier A., Malhotra A.K., Pinals D.A., Weisenfeld N.I., Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am. J. Psychiatry. 154:1997;805-811.
12. Canal N.M., Gourevitch R., Sandner G. Non-monotonic dependency of PPI on temporal parameters: differential alteration by ketamine and MK-801 as opposed to apomorphine and DOI. Psychopharmacology (Berl.). 156:2001;169-176.
13. Carlsson A., Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharm. Toxicol. 20:1963;140-144.
14. Carlsson M., Svensson A. Interfering with glutamatergic neurotransmission by means of NMDA antagonist administration discloses the locomotor stimulatory potential of other transmitter systems. Pharmacol. Biochem. Behav. 36:1990;45-50.
15. Carlsson A., Waters N., Carlsson M.L. Neurotransmitter interactions in schizophrenia-therapeutic implications. Eur. Arch. Psychiatry Clin. Neurosci. 249(Suppl. 4):1999;37-43.
16. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 41:2001;237-260.
17. Corbett R., Zhou L., Stephen M., Sorensen S.M., Mondadori C. Animal models of negative symptoms: M100907 antagonizes PCP-induced immobility in a forced swim test in mice. Neuropsychopharmacology. 21:1999;S211-S218.
18. Coutureau E., Lena I., Dauge V., Di S.G. The entorhinal cortex-nucleus accumbens pathway and latent inhibition: a behavioral and neurochemical study in rats. Behav. Neurosci. 116:2002;95-104.
19. Dean B. A predicted cortical serotonergic/cholinergic/GABAergic interface as a site of pathology in schizophrenia. Clin. Exp. Pharmacol. Physiol. 28:2001;74-78.
20. Dean B., Hussain T. Studies on dopaminergic and GABAergic markers in striatum reveals a decrease in the dopamine transporter in schizophrenia. Schizophr. Res. 52:2001;107-114.
21. de Bruin N.M., Ellenbroek B.A., Cools A.R., Coenen A.M., van Luijtelaar E.L. Differential effects of ketamine on gating of auditory evoked potentials and prepulse inhibition in rats. Psychopharmacology (Berl.). 142:1999;9-17.
22. Deutsch S.I., Rosse R.B., Schwartz B.L., Mastropaolo J. A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin. Neuropharmacol. 24:2001;43-49.
23. Duncan G.E., Moy S.S., Knapp D.J., Mueller R.A., Breese G.R. Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia. Brain Res. 787:1998;181-190.
24. Duncan G.E., Leipzig J.N., Mailman R.B., Lieberman J.A. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res. 812:1998;65-75.
25. Duncan G.E., Miyamoto S., Leipzig J.N., Lieberman J.A. Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res. 843:1999;171-183.
26. Duncan G.E., Sheitman B.B., Lieberman J.A. An integrated view of pathophysiological models of schizophrenia. Brain Res. Brain Res. Rev. 29:1999;250-264.
27. Duncan G.E., Miyamoto S., Leipzig J.N., Lieberman J.A. Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism. J. Pharmacol. Exp. Ther. 293:2000;8-14.
28. Duncan E.J., Madonick S.H., Parwani A., Angrist B., Rajan R., Chakravorty S., Efferen T.R., Szilagyi S., Stephanides M., Chappell P.B., Gonzenbach S., Ko G.N., Rotrosen J.P. Clinical and sensorimotor gating effects of ketamine in normals. Neuropsychopharmacology. 25:2001;72-83.
29. Ehrhardt J., Sabel B.A., Schroeder U. Subchronically applied phencyclidine fails to disrupt prepulse inhibition in rats. Eur. Neuropsychopharmacol. 10:1999;69-74.
30. Ellenbroek B.A., Cools A.R. Animal models with construct validity for schizophrenia. Behav. Pharmacol. 1:1990;469-490.
31. Ellison G. The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res. Brain Res. Rev. 20:1995;250-267.
32. Feldon J., Weiner I. From an animal model of an attentional deficit towards new insights into the pathophysiology of schizophrenia. J. Psychiatr. Res. 26:1992;345-366.
33. File, S.E., 1993. The social interaction test of anxiety. Neuroscience Protocols 93-010-01-07.
34. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl.). 156:2001;117-154.
35. Gispen-de Wied C.C. Stress in schizophrenia: an integrative view. Eur. J. Pharmacol. 405:2000;375-384.
36. Goff D.C., Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry. 158:2001;1367-1377.
37. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience. 41:1991;1-24.
38. Grecksch G., Bernstein H.G., Becker A., Höllt V., Bogerts B. Disruption of latent inhibition in rats with postnatal hippocampal lesions. Neuropsychopharmacology. 20:1999;525-532.
39. Gurevich E.V., Joyce J.N. Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol. Psychiatry. 42:1997;529-545.
40. Halberstadt A.L. The phencyclidine-glutamate model of schizophrenia. Clin. Neuropharmacol. 18:1995;237-249.
41. Hashimoto T., Nishino N., Nakai H., Tanaka C. Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci. 48:1991;355-363.
42. Javitt D.C. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J. Clin. Psychiatr. 9:1987;12-35.
43. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
44. Kapur S., Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D-2 and serotonin 5-HT2 receptors - implications for models of schizophrenia. Mol. Psychiatry. 7:2002;837-844.
45. Kegeles L.S., Abi-Dargham A., Zea-Ponce Y., Rodenhiser-Hill J., Mann J.J., Van Heertum R.L., Cooper T.B., Carlsson A., Laruelle M. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol. Psychiatry. 48:2000;627-640.
46. Kilts C.D. The changing roles and targets for animal models of schizophrenia. Biol. Psychiatry. 50:2001;845-855.
47. Koch M. The neurobiology of startle. Prog. Neurobiol. 59:1999;107-128.
48. Koch M., Schnitzler H.U. The acoustic startle response in rats - circuits mediating evocation, inhibition and potentiation. Behav. Brain Res. 89:1997;35-49.
49. Kornhuber J. Phencyclidine and schizophrenia. Am. J. Psychiatry. 149:1992;848-849.
50. Krupitsky E.M., Grinenko A.Y. Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. J. Psychoact. Drugs. 29:1997;165-183.
51. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B. Jr., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry. 51:1994;199-214.
52. Lahti A.C., Holcomb H.H., Medoff D.R., Tamminga C.A. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. NeuroReport. 6:1995;869-872.
53. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13:1995;9-19.
54. Lannes B., Micheletti G., Warter J.M., Kempf E., Di Scala G. Behavioural, pharmacological and biochemical effects of acute and chronic administration of ketamine in the rat. Neurosci. Lett. 128:1991;177-181.
55. Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res. Brain Res. Rev. 31:2000;371-384.
56. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. U.S.A. 93:1996;9235-9240.
57. Laruelle M., Abi-Dargham A., van Dyck C., Gil R., D'Souza D.C., Krystal J., Seibyl J., Baldwin R., Innis R. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. Biol. Psychiatry. 47:2000;371-379.
58. Lewis D.A. GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia. Brain Res. Brain Res. Rev. 31:2000;270-276.
59. Lewis D.A., Lieberman J.A. Catching up on schizophrenia: natural history and neurobiology. Neuron. 28:2000;325-334.
60. Lewis D.A., Pierri J.N., Volk D.W., Melchitzky D.S., Woo T.U. Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. Biol. Psychiatry. 46:1999;616-626.
61. Lieberman J.A., Sheitman B.B., Kinon B.J. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology. 17:1997;205-229.
62. Lowry O. II, Rosebrough R.N., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
63. Lubow R.E., De la C.G. Latent inhibition as a function of schizotypality and gender: implications for schizophrenia. Biol. Psychol. 59:2002;69-86.
64. Luby E.D., Cohen B.D., Rosenblaum G., Gottlieb J.S., Kelly R. Study of a new schizophrenomimetic drug - sernyl. Arch. Neurol. Psych. 81:1959;363-369.
65. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology. 17:1997;141-150.
66. Mansbach R.S., Geyer M.A. Parametric determinants in pre-stimulus modification of acoustic startle: interaction with ketamine. Psychopharmacology (Berl.). 105:1991;162-168.
67. Mansbach R.S., Carver J., Zorn S.H. Blockade of drug-induced deficits in prepulse inhibition of acoustic startle by ziprasidone. Pharmacol. Biochem. Behav. 69:2001;535-542.
68. Martinez Z.A., Ellison G.D., Geyer M.A., Swerdlow N.R. Effects of sustained phencyclidine exposure on sensorimotor gating of startle in rats. Neuropsychopharmacology. 21:1999;28-39.
69. Mechri A., Saoud M., Khiari G., d'Amato T., Dalery J., Gaha L. Hypothese glutamatergique de la schizophrenie: apports des recherches cliniques sur la ketamine. Encephale. 27:2001;53-59.
70. Miyamoto S., Leipzig J.N., Lieberman J.A., Duncan G.E. Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice. Neuropsychopharmacology. 22:2000;400-412.
71. Miyamoto S., Mailman R.B., Lieberman J.A., Duncan G.E. Blunted brain metabolic response to ketamine in mice lacking D(1A) dopamine receptors. Brain Res. 894:2001;167-180.
72. Moghaddam B. Recent basic findings in support of excitatory amino acid hypotheses of schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 18:1994;859-870.
73. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17:1997;2921-2927.
74. Morita T., Sonoda R., Nakato K., Koshiya K., Wanibuchi F., Yamaguchi T. Phencyclidine-induced abnormal behaviors in rats as measured by the hole board apparatus. Psychopharmacology (Berl.). 148:2000;281-288.
75. Murray T.F., Horita A. Effects of monoamine oxidase inhibitors on phencyclidine induced stereotyped behavior and brain levels in rats. Proc. West. Pharmacol. Soc. 22:1979;145-147.
76. Murray T.F., Horita A. Phencyclidine-induced stereotyped behavior in rats: dose response effects and antagonism by neuroleptics. Life Sci. 24:1979;2217-2225.
77. Ogawa S., Okuyama S., Araki H., Nakazato A., Otomo S. A rat model of phencyclidine psychosis. Life Sci. 55:1994;1605-1610.
78. Olney J.W., Farber N.B. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology. 13:1995;335-345.
79. Olney J.W., Labruyere J., Price M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 244:1989;1360-1362.
80. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. 33:1999;523-533.
81. Pal H.R., Berry N., Kumar R., Ray R. Ketamine dependence. Anaesth. Intensive Care. 30:2002;382-384.
82. Rascle C., Mazas O., Vaiva G., Tournant M., Raybois O., Goudemand M., Thomas P. Clinical features of latent inhibition in schizophrenia. Schizophr. Res. 51:2001;149-161.
83. Reynolds G.P., Beasley C.L. GABAergic neuronal subtypes in the human frontal cortex - development and deficits in schizophrenia. J. Chem. Neuroanat. 22:2001;95-100.
84. Sams-Dodd F.F. Distinct effects of D-amphetamine and phencyclidine on the social behaviour of rats. Behav. Pharmacol. 6:1995;55-65.
85. Sams-Dodd F.F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav. Pharmacol. 7:1996;3-23.
86. Sams-Dodd F. Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav. Pharmacol. 8:1997;196-215.
87. Sams-Dodd F. A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine. Neuropsychopharmacology. 18:1998;293-304.
88. Sams-Dodd F. Effects of diazepam, citalopram, methadone and naloxone on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Neurosci. Biobehav. Rev. 23:1998;287-293.
89. Sams-Dodd F. Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Rev. Neurosci. 10:1999;59-90.
90. Sams-Dodd F., Lipska B.K., Weinberger D.R. Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology (Berl.). 132:1997;303-310.
91. Scarr E., Copolov D.L., Dean B. A proposed pathological model in the hippocampus of subjects with schizophrenia. Clin. Exp. Pharmacol. Physiol. 28:2001;70-73.
92. Schröder H., Becker A., Lössner B. Glutamate binding to brain membranes is increased in pentylenetetrazole-kindled rats. J. Neurochem. 60:1993;1007-1011.
93. Schroeder U., Schroeder H., Darius J., Grecksch G., Sabel B.A. Simulation of psychosis by continuous delivery of phencyclidine from controlled-release polymer implants. Behav. Brain Res. 97:1998;59-68.
94. Schroeder H., Grecksch G., Becker A., Bogerts B., Hoellt V. Alterations of the dopaminergic and glutamatergic neurotransmission in adult rats with postnatal ibotenic acid hippocampal lesion. Psychopharmacology (Berl.). 145:1999;61-66.
95. Schroeder U., Schroeder H., Schwegler H., Sabel B.A. Neuroleptics ameliorate phencyclidine-induced impairments of short-term memory. Br. J. Pharmacol. 130:2000;33-40.
96. Sheitman B.B., Lieberman J.A. The natural history and pathophysiology of treatment resistant schizophrenia. J. Psychiatr. Res. 32:1998;143-150.
97. Shiigi Y., Casey D.E. Behavioral effects of ketamine, an NMDA glutamatergic antagonist, in non-human primates. Psychopharmacology (Berl.). 146:1999;67-72.
98. Simpson M.D., Slater P., Royston M.C., Deakin J.F. Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication. Schizophr. Res. 6:1991;41-48.
99. Steinpresis R.E. The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis. Behav. Brain Res. 74:1996;45-55.
100. Swerdlow N.R., Geyer M.A. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr. Bull. 24:1998;285-301.
101. Swerdlow N.R., Braff D.L., Hartston H., Perry W., Geyer M.A. Latent inhibition in schizophrenia. Schizophr. Res. 20:1996;91-103.
102. Swerdlow N.R., Bakshi V., Waikar M., Taaid N., Geyer M.A. Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psychopharmacology (Berl.). 140:1998;75-80.
103. Tamminga C. Glutamatergic aspects of schizophrenia. Br. J. Psychiatr., Suppl. 1999;12-15.
104. Tsai G., van Kammen D.P., Chen S., Kelley M.E., Grier A., Coyle J.T. Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Biol. Psychiatry. 44:1998;667-674.
105. Turgeon S.M., Roche J.K. The delayed effects of phencyclidine enhance amphetamine-induced behavior and striatal C-Fos expression in the rat. Neuroscience. 91:1999;1265-1275.
106. Umbricht D., Schmid L., Koller R., Vollenweider F.X., Hell D., Javitt D.C. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch. Gen. Psychiatry. 57:2000;1139-1147.
107. Vaitl D., Lipp O., Bauer U., Schuler G., Stark R., Zimmermann M., Kirsch P. Latent inhibition and schizophrenia: Pavlovian conditioning of autonomic responses. Schizophr. Res. 55:2002;147-158.
108. van Berckel B.N., Oranje B., van Ree J.M., Verbaten M.N., Kahn R.S. The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects. Psychopharmacology (Berl.). 137:1998;271-281.
109. Volk D., Austin M., Pierri J., Sampson A., Lewis D. GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons. Am. J. Psychiatry. 158:2001;256-265.
110. Weiner I., Feldon J. Phencyclidine does not disrupt latent inhibition in rats: implications for animal models of schizophrenia. Pharmacol. Biochem. Behav. 42:1992;625-631.
111. Weiner I., Feldon J. The switching model of latent inhibition: an update of neural substrates. Behav. Brain Res. 88:1997;11-25.
112. Weiner I., Gaisler I., Schiller D., Green A., Zuckerman L., Joel D. Screening of antipsychotic drugs in animal models. Drug Dev. Res. 50:2000;235-249.
113. Williams J.H., Wellman N.A., Geaney D.P., Cowen P.J., Feldon J., Rawlins J.N. Reduced latent inhibition in people with schizophrenia: an effect of psychosis or of 1st treatment. Br. J. Psychiatry. 172:1998;243-249.
114. Yui K., Goto K., Ikemoto S., Ishiguro T., Angrist B., Duncan G.E., Sheitman B.B., Lieberman J.A., Bracha S.H., Ali S.F. Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization. Mol. Psychiatry. 1999;512-523.
115. Zukin S.R., Young A.B., Snyder S.H. Gamma-aminobutyric acid binding to receptor sites in the central nervous system. Proc. Natl. Acad. Sci. U.S.A. 71:1974;4802-4807.